Lung Cancer

Lung cancer spans NSCLC and SCLC with recurrent drivers (EGFR, ALK, ROS1, RET, MET, BRAF, KRAS G12C). Immunotherapy response links to PD-L1, TMB, and microenvironment state. We provide subtype biomarker antibodies and TKIs plus MAPK/PI3K probes for resistant clones and combinations.

Focus areas: TKI bypass resistance, post–KRAS G12C clonal evolution, SCLC neuroendocrine programs & chemo-IO, brain metastasis models

Lung cancer–related antibodies (curated)

Loading…

Hot topics & directions

EGFR-TKI resistance: MET amplification, histologic transformation, C797S detection.
ALK/ROS1 fusions: Resistance mutation spectra vs CNS penetration extrapolation.
KRAS G12C inhibitors: Adaptive feedback (RTK/MAPK) and combo timing.
IO biomarkers: PD-L1, TMB, STK11/KEAP1 contextual stratification.

Related targets

RTK / fusion drivers

EGFR, ALK, ROS1, RET, MET, ERBB2, NTRK1/2/3

MAPK / RAS

KRAS, NRAS, BRAF, MAP2K1/2, MAPK1/3

Tumor suppressors / DDR

TP53, STK11, KEAP1, SMARCA4, ATM

Immune checkpoints

CD274 (PD-L1), PDCD1, CTLA4

Key signaling pathways

RTK–RAS–MAPK
Core oncogenic survival; bypass drives TKI resistance.
PI3K–AKT–mTOR
Anabolic programs; RTK feedback shapes tolerance.
Cell cycle / DDR
TP53/LKB1 context shifts therapeutic vulnerabilities.
IFNγ–PD-L1 轴
Inflammation couples to T-cell dysfunction.

Tool compounds (research use)

Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.

Compound	Targets / pathways	Experimental notes
Osimertinib	EGFR (incl. T790M/C797S contexts)	Third-gen TKI probe; QT/ILD vigilance.
Alectinib	ALK	CNS-penetrant ALK inhibition; animal dose translation.
Sotorasib	KRAS G12C	KRAS G12C validation; hepatic DDI monitoring.
Trametinib	MEK1/2	MAPK feedback probe; rash/cardiac baseline.
Crizotinib	ALK / ROS1 / MET	Multi-target TKI for fusion-positive mechanistic readouts.
Capmatinib	MET	MET exon14/amplification functional validation.
Pembrolizumab (anti-PD-1 mAb)	PD-1	Common IO research tool; monitor irAEs.